NDA 022252 · Bayer Hlthcare
Natazia
Dienogest, Estradiol Valerate · Oral
NovelLast checked: Nov 20, 2026Latest source record: Jun 26, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
May 6, 2010
Approved uses
3
Original approval plus efficacy supplements
Registered trials
59
22 Phase 3, 3 recruiting
FAERS reports
322
63 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke. [See Contraindications ( 4 ).] WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See full prescribing information for complete boxed warning. • Women over 35 years old who smoke should not use Natazia. ( 4 ) • Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. ( 4 )
What it is approved for
From the label in effect Jun 26, 2024.
• Natazia is a combination of dienogest , a progestin, and estradiol valerate, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy. ( 1 ) • The efficacy of Natazia in females of reproductive potential with a body mass index (BMI) of >30 kg/m 2 has not been evaluated. ( 1 , 8.8 ) • Treatment of heavy menstrual bleeding in females of reproductive potential without organic pathology who choose to use an oral contraceptive as their method of contraception. ( 1.2 ) 1.1 Oral Contraception Natazia ® is indicated for use by women to prevent pregnancy. The efficacy of Natazia in women with a body mass index (BMI) of > 30 kg/m 2 has not been evaluated. 1.2 Heavy Menstrual Bleeding Natazia is also indicated for the treatment of heavy menstrual bleeding in women without organic pathology who choose to use an oral contraceptive as their method of contraception [see Clinical Studies ( 14.2 )].
Mechanism: COCs lower the risk of becoming pregnant primarily by suppressing ovulation.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 14, 2012 Original approval · Efficacy NovelLabelPediatric Medical ReviewPediatric Clinical Pharmacology Review
- Feb 13, 2012 Supplement 1 · Efficacy LabelLetter
- May 6, 2010 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination NovelLetterLabelReview
1 products under this application
- NATAZIA · DIENOGEST N/A,2MG,3MG,N/A,N/A; ESTRADIOL VALERATE 3MG,2MG,2MG,1MG,N/A · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Dienogest" as an intervention, any sponsor and status, largest first.
- Study on Safety and Efficacy of an Oral Contraceptive in Treating Acne PapulopustulosaPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00280657 · 1,326 participants · Start Mar 10, 2004 · Primary completion May 21, 2005
Drug: Valette; Diane and 1 more · For: Acne Vulgaris
Sites: Chomutov, Czechia; Čáslav, Czechia; Kutná Hora, Czechia · 62 sites in all
- Bleeding Pattern StudyPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00302666 · 1,315 participants · Start Jun 2003
Drug: Valette (Dienogest/EE30, BAY86-5038); Valette (Dienogest/EE30, BAY86-5038) · For: Oral Contraceptive
Sites: Eberbach, Germany; Höchstadt A. D. Aisch, Germany; Krumbach, Germany · 48 sites in all
- A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 CyclesPivotal-lookingCompleted
Insud PharmaIndustry
NCT03945513 · 1,034 participants · Start Dec 3, 2019 · Primary completion Jun 30, 2023
Drug: LPRI424 (dienogest/ethinylestradiol) · For: Contraception
Sites: Savannah, Georgia
- Efficacy and Safety of a Combined Oral Contraceptive of Estradiol Valerate and Dienogest in Healthy Female SubjectsPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT01638910 · 955 participants · Start Jun 2012 · Primary completion Nov 2014
Drug: EV/DNG (Qlaira, BAY86-5027) · For: Contraception
Sites: Guangzhou, China; Shijiazhuang, China; Wuhan, China · 39 sites in all
- Effects of Dienogest and Dienogest Plus Estradiol Valerate in Ovarian EndometriomaPivotal-lookingStatus unknown
Bagcilar Training and Research HospitalGovernment (non-federal)
NCT03789123 · 710 participants (planned) · Start Jan 1, 2019 · Primary completion Jul 1, 2019
Drug: Estradiol valerate/dienogest · For: Ovarian Reserve
Sites: Istanbul, Turkey (Türkiye)
- Effect on Primary DysmenorrheaPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00909857 · 507 participants · Start Apr 2009 · Primary completion Nov 2010
Drug: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027); Ethinyl estradiol, Levonorgestrel (Miranova) and 2 more · For: Primary Dysmenorrhea
Sites: Tucson, Arizona; San Diego, California; Hialeah, Florida · 41 sites in all
- Adenomyosis and ARTPivotal-lookingStatus unknown
Azienda Ospedaliero-Universitaria di ModenaAcademic, hospital or other
NCT05937490 · 500 participants (planned) · Start Mar 27, 2023 · Primary completion Mar 2025
Drug: Enantone; Dienogest 2 MG (milligram) and 2 more · For: Adenomyosis
Sites: Modena, Italy
- Efficacy and Safety Study of an Oral Contraceptive in Healthy FemalesPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00206583 · 499 participants · Start Mar 2005 · Primary completion Jun 2007
Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658ID) · For: Contraception
Sites: Los Angeles, California; Palo Alto, California; San Diego, California · 29 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- metrorrhagia35
- drug dose omission34
- headache18
- vaginal haemorrhage15
- off label use14
- menstruation delayed12
- pregnancy on oral contraceptive12
- nausea11
- product use issue11
- amenorrhoea10
- product use in unapproved indication10
- inappropriate schedule of drug administration9
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 12 |
| 2011 | 42 |
| 2012 | 43 |
| 2013 | 40 |
| 2014 | 26 |
| 2015 | 32 |
| 2016 | 22 |
| 2017 | 10 |
| 2018 | 16 |
| 2019 | 18 |
| 2020 | 13 |
| 2021 | 8 |
| 2022 | 10 |
| 2023 | 6 |
| 2024 | 5 |
| 2025 | 7 |
| 2026 | 12 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Natazia (Estradiol Valerate/Dienogest)
2024 spending
$99K
Beneficiaries
50
219 claims
Per beneficiary
$1,989
$8.79 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $106,854 |
| 2021 | $108,158 |
| 2022 | $124,311 |
| 2023 | $121,123 |
| 2024 | $99,448 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacologic Interventions for Endometriosis-Related Pain: A Systematic Review and Meta-analysis.
Kou L, Huang C, Xiao D, et al. · Obstet Gynecol 2025 · Systematic Review, Network Meta-Analysis
- Medical Management of Ovarian Endometriomas: A Systematic Review and Meta-analysis.
Eberle A, Nguyen DB, Smith JP, et al. · Obstet Gynecol 2024 · Meta-Analysis, Systematic Review
- The Effect of Hormonal Treatment on Ovarian Endometriomas: A Systematic Review and Meta-Analysis.
Thiel PS, Donders F, Kobylianskii A, et al. · J Minim Invasive Gynecol 2024 · Meta-Analysis, Systematic Review
- The Efficacy of Dienogest in Reducing Disease and Pain Recurrence After Endometriosis Surgery: a Systematic Review and Meta-Analysis.
Muzii L, Di Tucci C, Galati G, et al. · Reprod Sci 2023 · Meta-Analysis, Systematic Review
- Dienogest vs. combined oral contraceptive: A systematic review and meta-analysis of efficacy and side effects to inform evidence-based guidelines.
Piacenti I, Tius V, Viscardi MF, et al. · Acta Obstet Gynecol Scand 2025 · Systematic Review, Meta-Analysis
- Efficacy of dienogest vs combined oral contraceptive on pain associated with endometriosis: Randomized clinical trial.
El Taha L, Abu Musa A, Khalifeh D, et al. · Eur J Obstet Gynecol Reprod Biol 2021 · Randomized Controlled Trial
Sponsor: Bayer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.